Summary

The global lipid nanoparticles market is expected to reach USD 350.5 million by 2029, from USD 271.8 million in 2024, at a CAGR of 5.2% from 2024 to 2029.
The global lipid nanoparticles services market is projected to reach USD 135.5 million in 2024 to USD 238.1 million in 2029, at a CAGR of 11.9% of during the forecast period of 2024 to 2029.
The growth of the lipid nanoparticles market has been significantly driven by the increasing use of lipid nanoparticles by players for the drug development of RNA therapeutics, personalized medicine, oncology & other therapies. Being a novel excipient for injectable therapies, limited regulatory approvals and resulting lack of established regulatory processes for lipid nanoparticle production are likely to deter the growth of the market.
" The Covid-19 commercial application segment was the highest share holding segment by application in 2023."
The commercial application segment under Covid-19 was the highest share holding segment in 2023 in the global lipid nanoparticles market. Lipid nanoparticles (LNP) usage in mRNA based COVID-19 vaccines due to their ability to enhance the stability and availability of mRNA was one of the drivers for establishing this market. With the decline in COVID-19 vaccinations, it is expected that clinical applications such as development of RNA therapeutics & LNP based drugs for oncology and other indications will drive the growth in this market.
“The US has continued to dominate the lipid nanoparticles market during the forecast period of 2024-2029.”
Two main mRNA-based COVID-19 vaccine producers that have shown success are Pfizer-BioNTech and Moderna, who have generated billions of doses together. With US government initiative such as Operation Warp Speed, US based biopharmaceutical companies have developed signicant capacities for RNA & LNP production as well as capabilities for development of LNP based drugs. Established LNP & RNA ecosystem and drug development activities from pharmaceutical & biotech companies as well as CDMOs are expected to help the US market retain its leadership in lipid nanoparticles development & manufacturing.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of Companies Profiled in the Report:
Avanti Polar Lipids (Croda International plc) (US)
Merck KGaA (Germany)
Evonik Industries AG (Germany)
IOI Oleo Gmbh (Germany)
FUJIFILM Pharmaceuticals U.S.A., Inc. (US)
Nippon Fine Chemical (Japan)
Recipharm AB (Sweden)
Emergent (US)
EUROAPI (France)
Cayman Chemical (US)
CordenPharma (Switzerland)
NOF CORPOTATION (Japan)
Precision NanoSystems (Canada)
Gattefossé (France)
Acuitas Therapeutics (Canada)
Creative Biolabs (US)
Curapath (Spain)
Lipoid Gmbh (Germany)
Nanocs, Inc. (US)
MedKoo Biosciences, Inc. (US)
Polysciences, Inc. (US)
BIOVECTRA (Canada)
Ascendia Pharmaceuticals (US)
Curia Global, Inc. (US)
Vernal Biosciences (US)
Research Coverage:
This research report categorizes the lipid nanoparticles market by product (ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials), by LNP type (solid lipid nanoparticles, nanostructured lipid carriers, and other types), by molecule type (si RNA, m RNA, and other molecules), by application ((commercial (Polyneuropathy, Covid-19), clinical (Covid-19, cancer, other diseases)), by end user (pharmaceutical & biotechnologies companies, CDMO’s, academic & research institutes), by service type (formulation development services, manufacturing services, and other services), by end user of services (pharmaceutical & biotechnologies companies, academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the lipid nanoparticles market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, services, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the lipid nanoparticles market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall lipid nanoparticles market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing use of lipid nanoparticles in anti-cancer therapies, Increasing use of lipid nanoparticles in RNA-based therapies, Growing government focus on R&D of key players for the development of lipid nanoparticles-based drugs, restraints (Stringent regulations associated lipid nanoparticles, High cost and difficulties for production of lipid nanoparticles), opportunities (Growing demand for advanced drug delivery systems), and Challenges (Formulation related challenges).
• Product Development/Innovation: Detailed insights on newly launched products/services of the lipid nanoparticles market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, new services, untapped geographies, recent developments, and investments in the lipid nanoparticles market
• Competitive Assessment: Avanti Polar Lipids (Croda International plc) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), FUJIFILM Pharmaceuticals U.S.A., Inc. (US), Nippon Fine Chemical (Japan), Recipharm AB (Sweden), Emergent (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), NOF CORPORATION (Japan), IOI Oleo GmbH (Germany), among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS & EXCLUSIONS 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.4 YEARS CONSIDERED 33
1.5 CURRENCY CONSIDERED 33
1.5.1 VALUE UNIT 33
1.6 MARKET STAKEHOLDERS 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.1.1 SECONDARY DATA 35
2.1.2 PRIMARY DATA 36
2.2 MARKET ESTIMATION METHODOLOGY 37
2.2.1 GLOBAL MARKET ESTIMATION 38
2.2.2 INSIGHTS OF PRIMARY EXPERTS 40
2.3 MARKET GROWTH RATE PROJECTIONS 42
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 44
2.5 RESEARCH ASSUMPTIONS 44
2.6 RESEARCH LIMITATIONS 45
2.7 RISK ANALYSIS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 51
4.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW 51
4.2 ASIA PACIFIC: LNP RAW MATERIALS & SERVICES MARKET, BY PRODUCT 52
4.3 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
4.4 LNP RAW MATERIALS MARKET, BY END USER, 2023 54
4.5 LNP SERVICES MARKET, BY END USER, 2023 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Increasing use of lipid nanoparticles in anti-cancer research 56
5.2.1.2 High uptake in RNA-based therapeutic research 57
5.2.1.3 Growing government focus on R&D for LNP-based drugs 57
5.2.2 RESTRAINTS 58
5.2.2.1 Stringent regulatory requirements 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Growing demand for advanced drug delivery systems 59
5.2.4 CHALLENGES 59
5.2.4.1 Challenges associated with LNP formulation 59
5.2.5 INDUSTRY TRENDS 60
5.2.5.1 Growing preference for personalized medicine and targeted drug delivery 60
5.2.5.2 Advancements in mRNA-based vaccine technology 60
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 61
5.4 PRICING ANALYSIS 61
5.4.1 INDICATIVE SELLING PRICE OF LNP PRODUCTS, BY KEY PLAYER 61
5.4.2 INDICATIVE SELLING PRICE, BY PRODUCT 62
5.5 SUPPLY CHAIN ANALYSIS 63
5.6 VALUE CHAIN ANALYSIS 64
5.7 ECOSYSTEM ANALYSIS 68
5.7.1 LNP RAW MATERIALS & SERVICES MARKET: ROLE IN ECOSYSTEM 69
5.8 TECHNOLOGY ANALYSIS 70
5.8.1 KEY TECHNOLOGIES 70
5.8.1.1 Nanotechnology-based drug delivery 70
5.8.1.2 Nucleic acid delivery 70
5.8.2 COMPLEMENTARY TECHNOLOGIES 71
5.8.2.1 Drug encapsulation techniques 71
5.8.2.2 Surface modification and functionalization technologies 71
5.8.3 ADJACENT TECHNOLOGIES 71
5.8.3.1 Biotechnology & genetic engineering technologies 71
5.8.3.2 Nanotechnology-based formulation techniques 72
5.9 PATENT ANALYSIS 72
5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014–2023 72
5.9.2 INNOVATION AND PATENT APPLICATIONS 72
5.9.3 TOP APPLICANTS 72
5.10 KEY CONFERENCES & EVENTS, 2024–2025 76
5.11 REGULATORY LANDSCAPE 76
5.11.1 REGULATORY SCENARIO 76
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 78
5.12 PORTER’S FIVE FORCES ANALYSIS 82
5.12.1 DEGREE OF COMPETITION 83
5.12.2 BARGAINING POWER OF SUPPLIERS 83
5.12.3 BARGAINING POWER OF BUYERS 83
5.12.4 THREAT OF SUBSTITUTES 83
5.12.5 THREAT OF NEW ENTRANTS 83
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 84
5.13.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIPID NANOPARTICLES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 84
5.14 KEY BUYING CRITERIA 84
5.14.1 BUYING CRITERIA FOR LNP RAW MATERIALS 84
5.14.2 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER 85
5.14.3 BUYING CRITERIA FOR LNP SERVICES 86
5.14.4 BUYING CRITERIA FOR LNP SERVICES, BY END USER 86
5.15 INVESTMENT & FUNDING SCENARIO 88
5.16 IMPACT OF GENERATIVE AI ON LNP RAW MATERIALS & SERVICES MARKET 89
6 LNP RAW MATERIALS MARKET, BY PRODUCT 90
6.1 INTRODUCTION 91
6.2 IONIZABLE LIPIDS 91
6.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET 91
6.3 PEGYLATED LIPIDS 94
6.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND 94
6.4 NEUTRAL LIPIDS 95
6.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET 95
6.5 PHOSPHOLIPIDS 97
6.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH 97
6.6 KITS & REAGENTS 100
6.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET 100
6.7 OTHER FORMULATION MATERIALS 101
7 LNP RAW MATERIALS MARKET, BY LNP TYPE 102
7.1 INTRODUCTION 103
7.2 SOLID LIPID NANOPARTICLES (SLNS) 103
7.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET 103
7.3 NANOSTRUCTURED LIPID CARRIERS (NLCS) 106
7.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET 106
7.4 OTHER LNP TYPES 108
8 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE 111
8.1 INTRODUCTION 112
8.2 SIRNA 112
8.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET 112
8.3 MRNA 115
8.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET 115
8.4 OTHER MOLECULES 117
9 LNP RAW MATERIALS MARKET, BY APPLICATION 121
9.1 INTRODUCTION 122
9.2 COMMERCIAL APPLICATIONS 122
9.2.1 POLYNEUROPATHY 125
9.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand 125
9.2.2 COVID-19 127
9.2.2.1 Enhanced stability and distribution of mRNA to drive market 127
9.3 CLINICAL APPLICATIONS 130
9.3.1 COVID-19 132
9.3.1.1 Threat of evolving emerging variants to fuel uptake 132
9.3.2 CANCER 135
9.3.2.1 Increasing focus on oncology therapeutics to drive market 135
9.3.3 OTHER CLINICAL APPLICATIONS 137
10 LNP RAW MATERIALS MARKET, BY END USER 140
10.1 INTRODUCTION 141
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 141
10.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET 141
10.3 ACADEMIC & RESEARCH INSTITUTES 144
10.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET 144
10.4 CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS (CDMOS) 146
10.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET 146
11 LNP SERVICES MARKET, BY SERVICE TYPE 149
11.1 INTRODUCTION 150
11.2 FORMULATION DEVELOPMENT SERVICES 150
11.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET 150
11.3 MANUFACTURING SERVICES 151
11.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY
AND VACCINE DEVELOPMENT TO DRIVE MARKET 151
11.4 OTHER SERVICES 152
12 LNP SERVICES MARKET, BY END USER 154
12.1 INTRODUCTION 155
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 155
12.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET 155
 
12.3 ACADEMIC & RESEARCH INSTITUTES 156
12.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH 156
13 LNP RAW MATERIALS & SERVICES MARKET, BY REGION 158
13.1 INTRODUCTION 159
13.2 NORTH AMERICA 160
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 164
13.2.2 US 165
13.2.2.1 High pharmaceutical R&D expenditure to drive market 165
13.2.3 CANADA 168
13.2.3.1 Growing focus on personalized medicine to drive market 168
13.3 EUROPE 171
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 174
13.3.2 GERMANY 175
13.3.2.1 Rising development activities for LNP production to drive market 175
13.3.3 UK 177
13.3.3.1 Pioneering research programs for drug delivery systems to boost demand 177
13.3.4 FRANCE 180
13.3.4.1 Government funding for proteomics and genomics research to support market growth 180
13.3.5 ITALY 183
13.3.5.1 Growth in life sciences research to propel market 183
13.3.6 SPAIN 185
13.3.6.1 Growing demand for cancer therapeutics to drive market 185
13.3.7 REST OF EUROPE 188
13.4 ASIA PACIFIC 191
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 195
13.4.2 CHINA 196
13.4.2.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market 196
13.4.3 JAPAN 199
13.4.3.1 Demand for LNP-based mRNA vaccines to fuel market 199
13.4.4 INDIA 201
13.4.4.1 Growth in pharmaceutical industry to drive market 201
13.4.5 SOUTH KOREA 204
13.4.5.1 Rising number of clinical trials to boost demand 204
13.4.6 AUSTRALIA 207
13.4.6.1 Growing requirement for innovative drug delivery systems to propel market 207
13.4.7 REST OF ASIA PACIFIC 210
 
13.5 LATIN AMERICA 212
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 216
13.5.2 BRAZIL 216
13.5.2.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake 216
13.5.3 MEXICO 219
13.5.3.1 Large target patient population and demand for novel drug delivery technology to drive market 219
13.5.4 REST OF LATIN AMERICA 222
13.6 MIDDLE EAST 224
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 228
13.6.2 GCC COUNTRIES 228
13.6.2.1 Economic & healthcare expansion to support market growth 228
13.6.3 REST OF MIDDLE EAST 231
13.7 AFRICA 234
13.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 234
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 237
14 COMPETITIVE LANDSCAPE 238
14.1 INTRODUCTION 238
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN 238
14.3 REVENUE ANALYSIS 240
14.4 MARKET SHARE ANALYSIS 241
14.4.1 LNP SERVICES MARKET 242
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 244
14.5.1 STARS 244
14.5.2 EMERGING LEADERS 244
14.5.3 PERVASIVE PLAYERS 244
14.5.4 PARTICIPANTS 245
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 246
14.5.5.1 Company footprint 246
14.5.5.2 Product footprint 247
14.5.5.3 Application footprint 248
14.5.5.4 Service type footprint 249
14.5.5.5 Region footprint 250
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 251
14.6.1 PROGRESSIVE COMPANIES 251
14.6.2 RESPONSIVE COMPANIES 251
14.6.3 DYNAMIC COMPANIES 251
14.6.4 STARTING BLOCKS 251
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 253
 
14.7 COMPANY VALUATION & FINANCIAL METRICS 254
14.7.1 FINANCIAL METRICS 254
14.7.2 COMPANY VALUATION 255
14.8 BRAND/PRODUCT COMPARISON ANALYSIS 256
14.9 COMPETITIVE SCENARIO 257
14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 257
14.9.2 DEALS 258
14.9.3 EXPANSIONS 260
15 COMPANY PROFILES 261
15.1 KEY PLAYERS 261
15.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC) 261
15.1.1.1 Business overview 261
15.1.1.2 Products/Services offered 263
15.1.1.3 Recent developments 264
15.1.1.3.1 Deals 264
15.1.1.4 MnM view 264
15.1.1.4.1 Key strengths 264
15.1.1.4.2 Strategic choices 264
15.1.1.4.3 Weaknesses & competitive threats 264
15.1.2 MERCK KGAA 265
15.1.2.1 Business overview 265
15.1.2.2 Products/Services offered 267
15.1.2.3 Recent developments 268
15.1.2.3.1 Deals 268
15.1.2.3.2 Expansions 268
15.1.2.4 MnM view 269
15.1.2.4.1 Key strengths 269
15.1.2.4.2 Strategic choices 269
15.1.2.4.3 Weaknesses & competitive threats 269
15.1.3 EVONIK INDUSTRIES AG 270
15.1.3.1 Business overview 270
15.1.3.2 Products/Services offered 271
15.1.3.3 Recent developments 272
15.1.3.3.1 Deals 272
15.1.3.4 MnM view 272
15.1.3.4.1 Key strengths 272
15.1.3.4.2 Strategic choices 272
15.1.3.4.3 Weaknesses & competitive threats 272
15.1.4 NIPPON FINE CHEMICAL 273
15.1.4.1 Business overview 273
15.1.4.2 Products/Services offered 274
15.1.4.3 MnM view 275
15.1.4.3.1 Key strengths 275
15.1.4.3.2 Strategic choices 275
15.1.4.3.3 Weaknesses & competitive threats 275
15.1.5 NOF CORPORATION 276
15.1.5.1 Business overview 276
15.1.5.2 Products/Services offered 278
15.1.5.3 Recent developments 279
15.1.5.3.1 Deals 279
15.1.5.4 MnM view 279
15.1.5.4.1 Key strengths 279
15.1.5.4.2 Strategic choices 279
15.1.5.4.3 Weaknesses & competitive threats 279
15.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC.
(FUJIFILM HOLDINGS CORPORATION) 280
15.1.6.1 Business overview 280
15.1.6.2 Products/Services offered 281
15.1.6.3 Recent developments 282
15.1.6.3.1 Expansions 282
15.1.7 PRECISION NANOSYSTEMS (CYTIVA) 283
15.1.7.1 Business overview 283
15.1.7.2 Products/Services offered 283
15.1.7.3 Recent developments 284
15.1.7.3.1 Product/Service launches 284
15.1.7.3.2 Deals 285
15.1.7.3.3 Expansions 285
15.1.8 RECIPHARM AB 286
15.1.8.1 Business overview 286
15.1.8.2 Products/Services offered 287
15.1.8.3 Recent developments 287
15.1.8.3.1 Deals 287
15.1.9 EMERGENT 288
15.1.9.1 Business overview 288
15.1.9.2 Products/Services offered 289
15.1.9.3 Recent developments 290
15.1.9.3.1 Deals 290
15.1.10 EUROAPI 291
15.1.10.1 Business overview 291
15.1.10.2 Products/Services offered 292
15.1.11 CAYMAN CHEMICAL 293
15.1.11.1 Business overview 293
15.1.11.2 Products/Services offered 293
15.1.12 CORDENPHARMA 294
15.1.12.1 Business overview 294
15.1.12.2 Products/Services offered 294
15.1.12.3 Recent developments 295
15.1.12.3.1 Product/Service launches 295
15.1.12.3.2 Deals 295
15.1.12.3.3 Expansions 295
15.1.13 GATTEFOSSÉ 296
15.1.13.1 Business overview 296
15.1.13.2 Products/Services offered 296
15.1.14 ACUITAS THERAPEUTICS 297
15.1.14.1 Business overview 297
15.1.14.2 Products/Services offered 297
15.1.14.3 Recent developments 298
15.1.14.3.1 Deals 298
15.1.15 IOI OLEO GMBH 299
15.1.15.1 Business overview 299
15.1.15.2 Products/Services offered 300
15.2 OTHER PLAYERS 301
15.2.1 CREATIVE BIOLABS 301
15.2.2 CURAPATH 302
15.2.3 LIPOID GMBH 303
15.2.4 NANOCS INC. 304
15.2.5 MEDKOO BIOSCIENCES, INC. 305
15.2.6 POLYSCIENCES INC. 305
15.2.7 BIOVECTRA 306
15.2.8 ASCENDIA PHARMACEUTICALS 306
15.2.9 CURIA GLOBAL, INC. 307
15.2.10 VERNAL BIOSCIENCES 307
16 APPENDIX 308
16.1 DISCUSSION GUIDE 308
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 313
16.3 CUSTOMIZATION OPTIONS 315
16.4 RELATED REPORTS 315
16.5 AUTHOR DETAILS 316